Malignant mediastinum hemangiopericytoma

Summary

Malignant mediastinum hemangiopericytoma (MONDO:0003809) is a disease. A subtype of hemangiopericytoma, malignant — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant mediastinum hemangiopericytoma
Mondo ID	MONDO:0003809
DOID	DOID:6209
NCIT	C6608
UMLS	C1334598
MedGen	235298
GARD	0023679
Anatomy (UBERON)	UBERON:0003728
Is cancer (heuristic)	no

Also known as: malignant hemangiopericytoma of mediastinum · malignant hemangiopericytoma of the mediastinum · malignant mediastinal hemangiopericytoma · mediastinum hemangiopericytoma · mediastinum spindle cell tumor · mediastinum spindle cell tumour

Disease family

This is a subtype of hemangiopericytoma, malignant. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › hemangiopericytoma, malignant › malignant mediastinum hemangiopericytoma

Related subtypes (3): conventional malignant hemangiopericytoma, adult malignant hemangiopericytoma, childhood malignant hemangiopericytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.